Outer retinal dysfunction in patients treated with vigabatrin

Neurology

Volumn 52, Issue 6, 1999, Pages 1201-1205

  Arndt, Carl ^a,c   Derambure, P ^b   Defoort Dhellemmes, S ^a   Hache, J C ^a  

^a Serv d'Explorations F   (France)

^b HÔpital Roger Salengro   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG MECHANISM; ELECTROOCULOGRAM; ELECTRORETINOGRAM; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DISEASE; SCHOOL CHILD; VISUAL ACUITY;

EID: 0032893143     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.6.1201     Document Type: Article

References (17)

1. John RA, Rimmer EM, Williams J, Cole G, Fowler LJ, Richens A. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin. Biochem Pharmacol 1987;36:1467-1473.
2. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-238.
3. Mauguiere F, Chauvel P, Dewailly J, Dousse N. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group. Epilepsia 1997;38:301-308.
4. Harding GF. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. BMJ 1997;314:1694. Letter.
5. Eke T. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181. Letter.
6. Wilson EA. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions. BMJ 1997;314:1693. Letter.
7. Backstrom JT. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies. BMJ 1997;314:1694-1695. Letter.
8. Blackwell N. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. BMJ 1997;314:1694. Letter.
9. Wong IC. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent. BMJ 1997;314:1693-1694. Letter.
10. Harding GF. Severe persistent visual field constriction associated with vigabatrin. Benefit:risk ratio must be calculated for individual patients. BMJ 1998;316:232-233. Letter.
11. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
12. Peterson WM, Miller SS. Identification and functional characterization of a dual GABA/taurine transporter in the bullfrog retinal pigment epithelium. J Gen Physiol 1995;106:1089-1122.
13. Marmor MF, Zrenner E. Standard for clinical electrooculography. International Society for Clinical Electrophysiology of Vision. Arch Ophthalmol 1993;111:601-604.
14. International Standardization Committee. Standard for Clinical Electroretinography. Arch Ophthalmol 1989;107:816-819.
15. Burke JM, McKay BS, Jaffe GJ. Retinal pigment epithelial cells of the posterior pole have fewer Na/K adenosine triphosphatase pumps than peripheral cells. Invest Ophthalmol Vis Sci 1991;32:2042-2046.
16. Krill AE, Morse PA, Potts AM, Klien BA. Hereditary vitelliruptive macular degeneration. Am J Ophthalmol 1966;61: 1405-1415.
17. Bresnick GH, North K, Groo A. Electroretinographic oscillatory potentials predict progression of diabetic retinopathy: preliminary report. Invest Ophthalmol Vis Sci 1984;25:128.